BRPI0117173A2 - produção constituida de alto nível de antígeno protetor para antraz - Google Patents

produção constituida de alto nível de antígeno protetor para antraz

Info

Publication number
BRPI0117173A2
BRPI0117173A2 BRPI0117173A BRPI0117173A BRPI0117173A2 BR PI0117173 A2 BRPI0117173 A2 BR PI0117173A2 BR PI0117173 A BRPI0117173 A BR PI0117173A BR PI0117173 A BRPI0117173 A BR PI0117173A BR PI0117173 A2 BRPI0117173 A2 BR PI0117173A2
Authority
BR
Brazil
Prior art keywords
cells
coli
level production
followed
high level
Prior art date
Application number
BRPI0117173A
Other languages
English (en)
Inventor
Bhatnagar Rakesh
Mohsin Waheed Syed
Chauhan Vibha
Original Assignee
Bhatnagar Rakesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhatnagar Rakesh filed Critical Bhatnagar Rakesh
Publication of BRPI0117173A2 publication Critical patent/BRPI0117173A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Laminated Bodies (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
BRPI0117173A 2001-11-05 2001-12-07 produção constituida de alto nível de antígeno protetor para antraz BRPI0117173A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1127DE2001 IN190590B (pt) 2001-11-05 2001-11-05
PCT/IN2001/000215 WO2003040179A1 (en) 2001-11-05 2001-12-07 High level constitutive production of anthrax protective antigen

Publications (1)

Publication Number Publication Date
BRPI0117173A2 true BRPI0117173A2 (pt) 2018-04-17

Family

ID=11097131

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0117173A BRPI0117173A2 (pt) 2001-11-05 2001-12-07 produção constituida de alto nível de antígeno protetor para antraz

Country Status (15)

Country Link
US (1) US7329513B2 (pt)
EP (1) EP1442052B1 (pt)
JP (1) JP2005510215A (pt)
CN (1) CN100347189C (pt)
AT (1) ATE484517T1 (pt)
BR (1) BRPI0117173A2 (pt)
CA (1) CA2465679A1 (pt)
DE (1) DE60143276D1 (pt)
IL (1) IL161725A0 (pt)
IN (1) IN190590B (pt)
MX (1) MXPA04004281A (pt)
RU (1) RU2288272C2 (pt)
UA (1) UA80809C2 (pt)
WO (1) WO2003040179A1 (pt)
ZA (1) ZA200403396B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80809C2 (en) * 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
CN1833030B (zh) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 用于表达、传递及纯化目标多肽的重组载体分子
AU2003271835A1 (en) * 2003-06-06 2005-01-04 Avecia Limited Process for the separation of proteins
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
EP1919504B1 (en) 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
GB0607462D0 (en) * 2006-04-13 2006-05-24 Avecia Ltd Assay
CA2651962A1 (en) * 2006-05-12 2007-12-21 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
WO2008115198A2 (en) 2006-06-30 2008-09-25 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates,synthesis and uses thereof
US8420607B2 (en) 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009126355A2 (en) * 2008-01-28 2009-10-15 Baxter International, Inc. Methods of increasing recombinant production of bacillus anthracis protective antigen
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
CA2738621C (en) 2008-10-02 2017-01-31 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US20120301951A1 (en) * 2010-11-18 2012-11-29 E. I. Du Pont De Nemours And Company Prevention of contamination of nutrient feed reservoirs & feed lines in bioreactor systems
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
CN115125224B (zh) * 2022-08-11 2023-07-18 福州大学 一种可规模化生产具有活性的dna聚合酶的方法
CN117093572A (zh) * 2023-08-24 2023-11-21 中国建设银行股份有限公司 数据补录方法、装置、设备、存储介质及产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591631A (en) * 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5800821A (en) * 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
ATE284957T1 (de) * 1998-04-07 2005-01-15 Wisconsin Alumni Res Found Enterotoxindefizierende bacillus
US20020086032A1 (en) * 1999-02-02 2002-07-04 Mahan Michael J. Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
WO2003055977A2 (en) * 2001-10-01 2003-07-10 Regents Of The University Of California A method for generating overexpression of alleles in genes of unknown function
UA80809C2 (en) * 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7763451B2 (en) * 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines

Also Published As

Publication number Publication date
CN100347189C (zh) 2007-11-07
HK1072610A1 (zh) 2005-09-02
IN190590B (pt) 2003-08-09
IL161725A0 (en) 2005-11-20
EP1442052B1 (en) 2010-10-13
WO2003040179A1 (en) 2003-05-15
UA80809C2 (en) 2007-11-12
CN1582298A (zh) 2005-02-16
DE60143276D1 (de) 2010-11-25
US7329513B2 (en) 2008-02-12
ZA200403396B (en) 2005-08-05
US20050054038A1 (en) 2005-03-10
RU2288272C2 (ru) 2006-11-27
ATE484517T1 (de) 2010-10-15
JP2005510215A (ja) 2005-04-21
MXPA04004281A (es) 2005-03-31
EP1442052A1 (en) 2004-08-04
RU2004117085A (ru) 2005-03-27
CA2465679A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
IL161725A0 (en) A process for preparing an anthrax protective antigen
Reif et al. Semisynthesis of biologically active glycoforms of the human cytokine interleukin 6
Duenas et al. Intra-and extracellular expression of an scFv antibody fragment in E. coli: effect of bacterial strains and pathway engineering using GroES/L chaperonins
DK1332222T3 (da) Stofskifteændringer i fermenteringer der udtrykker rekombinante proteiner
CA2417415A1 (en) Expression of biologically active polypeptides in duckweed
AU5053796A (en) Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. Coli
EA200600554A1 (ru) Способ получения рекомбинантных белков
CN104066841B (zh) 表达载体和蛋白质的制造方法
CN102659928B (zh) 一种人工合成的信号肽及其应用
US7186528B2 (en) Method for preparing a physiologically active IL-18 polypeptide
KR100614020B1 (ko) 폴리펩티드의 재조합 생산을 위한 향상된 방법
Kawasaki et al. Folding-Dependentin VitroProtein Splicing of theSaccharomyces cerevisiae VMA1Protozyme
EP3159411B1 (en) Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof
CN103483423B (zh) 一种人工合成的信号肽及其应用
CN101921315B (zh) 一种人工合成的信号肽及其应用
Schneider et al. Reduction of IL‐2 fragmentation during manufacturing of a novel immunocytokine by DoE process optimization
Lehmann et al. A novel S3S‐TAP‐tag for the isolation of T‐cell interaction partners of adhesion and degranulation promoting adaptor protein
Sekimoto Production and secretion of a biologically active Closterium sex pheromone by Saccharomyces cerevisiae
Kunes et al. Expression of antibodies using single‐open reading frame vector design and polyprotein processing from mammalian cells
Chen et al. Expression and analysis of thymosin α1 concatemer in Escherichia coli
CA2082802C (en) Method for expressing polypeptides in cyanobacteria
KR20090025479A (ko) ＳｌｙＤ를 융합파트너로 이용한 재조합 단백질의 제조방법
CN102659927B (zh) 一种人工合成的信号肽及其应用
ATE201903T1 (de) Peptide-familie, genannt xenoxine
US20080268503A1 (en) Method for Achieving High-Level Expression of Recombinant Human Interleukin-2 Upon Destabilization of the Rna Secondary Structure

Legal Events

Date Code Title Description
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]